ReviewGut microbes2025
Fecal microbiota transplantation: a tale of two regulatory pathways.
Review in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Gut microbiota regulate atherosclerosis via the gut-vascular axis: a scoping review of mechanisms and therapeutic interventions.Frontiers in microbiology · 2025Pooled it
- Clinical efficacy of fecal microbiota transplantation in alleviating depressive symptoms: a meta-analysis of randomized trials.Frontiers in psychiatry · 2025Pooled it
- Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitorsJournal of enzyme inhibition and medicinal chemistry · 2026Review
- Regenerative Microbiology: Harnessing Bacterial Antagonism and Spatiotemporal Signaling for Diabetic Wound Repair.Smart medicine · 2026Review
- Letter: Dose and Donor Matter-Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection. Authors' Reply.Alimentary pharmacology & therapeutics · 2026Article
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- Biovigilance in Faecal Microbiota Transplantation: 7-Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events.United European gastroenterology journal · 2026Observational
- Microbial reprogramming of immunogenic cell death: a new paradigm in tumor immunotherapy.Cancer biology & medicine · 2026Review
- Fecal microbiota transplantation in chronic liver disease: Current and future state of the art.Hepatology communications · 2026Review
- Fecal microbiota transplant and its usefulness in hepatic disorders: a systematic review.Therapeutic advances in gastroenterology · 2026Review
- Programming the tumor microenvironment through microbiome-driven mechanisms.Frontiers in cellular and infection microbiology · 2026Review
- Gut microbiota-host adaptive immune interactions in type 2 diabetes mellitus: mechanisms, disease progression, and microbiota-based therapeutic strategies.Frontiers in microbiology · 2026Review
- From gut microbiota dysbiosis to immune dysregulation: pathogenic mechanisms and emerging therapeutic perspectives in pediatric asthma.Frontiers in immunology · 2026Review
- Advances in Understanding the Impact of Human Gut Microbiota on Chemotherapy-Induced Neutropenia.Biomedicines · 2025Review
- Microbiome Therapeutics for Clostridioides difficile Infection.Infectious disease clinics of North America · 2025Review
- The challenges and opportunities in the expanding horizons of microbiota transplant therapies.Gut microbes · 2025Article
- Metabolic reprogramming in ischemic stroke: when glycolytic overdrive meets lipid storm.Cell death & disease · 2025Review
- Type 2 Diabetes and the Multifaceted Gut-X Axes.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fecal microbiota transplantation (FMT) is a procedure involving the transfer of intestinal microbiota from a healthy donor to a patient to restore a functional intestinal microbiome. First described in modern science in 1958, the use of FMT has been practiced for decades, but only during the past dozen years have clinical frameworks and legal regulations from competent authorities been developed. Future development of microbiota-derived medical therapies will be shaped by the regulatory frameworks of various jurisdictions. This review examines the historical development and status of FMT regulations in the United States and Europe, with particular attention to their respective approaches to ensuring the safety and quality of the therapeutic product and patient access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.